Jonathan J Duplisea1, Firas G Petros1, Roger Li1, Bryan Fellman2, Charles C Guo3, Bogdan A Czerniak3, Arlene O Siefker-Radtke4, John C Araujo4, Colin P N Dinney1, Surena F Matin5. 1. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. 3. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 5. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: surmatin@mdanderson.org.
Abstract
PURPOSE: Micropapillary variant upper tract urothelial cancer (MP-UTUC) is a rare malignancy with little known regarding its clinical course and/or optimal treatment. In this case series, we describe patient characteristics, surgical treatment, oncologic outcomes, and response to perioperative chemotherapy. MATERIALS AND METHODS: We conducted a review to identify patients with MP-UTUC treated at our center between January 1994 and October 2017. Clinicopathologic data was obtained. Descriptive statistics, Kaplan-Meier analysis, Cox proportional hazards, and nearest neighbor matching were used to examine the cohort. RESULTS: Eighteen, (4.3%) of 416 patients were found to have MP-UTUC at our institution over a 23-year period. The majority of patients had ≥pT3 disease at the time of extirpative surgery (13/18, 72%) and one was identified as MP-UTUC prior to surgery. Seven patients received neoadjuvant chemotherapy and six patients received adjuvant chemotherapy. Median overall, cancer specific, and recurrence free survival were 3.29, 3.29, and 1.69 years, respectively for MP-UTUC. There was no survival difference between conventional UTUC and MP-UTUC when matched for age, stage, grade, lymphovascular invasion, and margins (HR 1.18, P = 0.567). No MP-UTUC patients receiving neoadjuvant and adjuvant chemotherapy had apparent pathologic down staging, and of those receiving adjuvant chemotherapy two-thirds died of disease within 2 years. CONCLUSIONS: MP-UTUC is a rare, and in most cases aggressive malignancy that commonly presents as locally advanced disease. In this case series, MP-UTUC does not appear to respond to perioperative chemotherapy as neoadjuvant and adjuvant chemotherapy did not result in apparent pathologic down staging and the majority of those receiving adjuvant chemotherapy died from MP-UTUC.
PURPOSE:Micropapillary variant upper tract urothelial cancer (MP-UTUC) is a rare malignancy with little known regarding its clinical course and/or optimal treatment. In this case series, we describe patient characteristics, surgical treatment, oncologic outcomes, and response to perioperative chemotherapy. MATERIALS AND METHODS: We conducted a review to identify patients with MP-UTUC treated at our center between January 1994 and October 2017. Clinicopathologic data was obtained. Descriptive statistics, Kaplan-Meier analysis, Cox proportional hazards, and nearest neighbor matching were used to examine the cohort. RESULTS: Eighteen, (4.3%) of 416 patients were found to have MP-UTUC at our institution over a 23-year period. The majority of patients had ≥pT3 disease at the time of extirpative surgery (13/18, 72%) and one was identified as MP-UTUC prior to surgery. Seven patients received neoadjuvant chemotherapy and six patients received adjuvant chemotherapy. Median overall, cancer specific, and recurrence free survival were 3.29, 3.29, and 1.69 years, respectively for MP-UTUC. There was no survival difference between conventional UTUC and MP-UTUC when matched for age, stage, grade, lymphovascular invasion, and margins (HR 1.18, P = 0.567). No MP-UTUC patients receiving neoadjuvant and adjuvant chemotherapy had apparent pathologic down staging, and of those receiving adjuvant chemotherapy two-thirds died of disease within 2 years. CONCLUSIONS: MP-UTUC is a rare, and in most cases aggressive malignancy that commonly presents as locally advanced disease. In this case series, MP-UTUC does not appear to respond to perioperative chemotherapy as neoadjuvant and adjuvant chemotherapy did not result in apparent pathologic down staging and the majority of those receiving adjuvant chemotherapy died from MP-UTUC.
Authors: Vitaly Margulis; Ramy F Youssef; Pierre I Karakiewicz; Yair Lotan; Christopher G Wood; Richard Zigeuner; Eiji Kikuchi; Alon Weizer; Jay D Raman; Mesut Remzi; Marco Roscigno; Francesco Montorsi; Christian Bolenz; Wassim Kassouf; Shahrokh F Shariat Journal: J Urol Date: 2010-06-17 Impact factor: 7.450
Authors: Sima Porten; Arlene O Siefker-Radtke; Lianchun Xiao; Vitaly Margulis; Ashish M Kamat; Christopher G Wood; Eric Jonasch; Colin P N Dinney; Surena F Matin Journal: Cancer Date: 2014-03-13 Impact factor: 6.860
Authors: Alexandra Masson-Lecomte; Pierre Colin; Gregory Bozzini; Laurent Nison; Alexandre de La Taille; Eva Comperat; Marc Zerbib; François Rozet; Xavier Cathelineau; Antoine Valeri; Alain Ruffion; Laurent Guy; Stéphane Droupy; Olivier Cussenot; Morgan Rouprêt Journal: World J Urol Date: 2013-08-02 Impact factor: 4.226
Authors: Malte W Vetterlein; Stephanie A M Wankowicz; Thomas Seisen; Richard Lander; Björn Löppenberg; Felix K-H Chun; Mani Menon; Maxine Sun; Justine A Barletta; Toni K Choueiri; Joaquim Bellmunt; Quoc-Dien Trinh; Mark A Preston Journal: Cancer Date: 2017-07-25 Impact factor: 6.860
Authors: Arlene O Siefker-Radtke; Colin P Dinney; Yu Shen; Dallas L Williams; Ashish M Kamat; H Barton Grossman; Randall E Millikan Journal: Cancer Date: 2012-08-22 Impact factor: 6.860
Authors: Marco Roscigno; Shahrokh F Shariat; Vitaly Margulis; Pierre Karakiewicz; Mesut Remzi; Eiji Kikuchi; Cord Langner; Yair Lotan; Alon Weizer; Karim Bensalah; Jay D Raman; Christian Bolenz; Charles C Guo; Christopher G Wood; Richard Zigeuner; Jeffrey Wheat; Wareef Kabbani; Theresa M Koppie; Casey K Ng; Nazareno Suardi; Roberto Bertini; Mario I Fernández; Shuji Mikami; Masaru Isida; Maurice Stephan Michel; Francesco Montorsi Journal: J Urol Date: 2009-04-16 Impact factor: 7.450